Author(s):
Magendran Rajendiran, Shanmugasundaram Palani
Email(s):
magendran1988@gmail.com , dean.sps@vistas.ac.in
DOI:
10.52711/0974-360X.2026.00435 
Address:
Magendran Rajendiran, Shanmugasundaram Palani*
School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Studies (VISTAS), Pallavaram, Chennai, Tamil Nadu 600117, India.
*Corresponding Author
Published In:
Volume - 19,
Issue - 7,
Year - 2026
ABSTRACT:
Obesity is a complicated and escalating health issue globally, intricately associated with metabolic syndromes and a marked reduction in life expectancy. Central to the regulation of energy homeostasis and appetite are key neuroendocrine receptors, notably leptin and ghrelin. In this research study, a structure-based molecular docking strategy was employed to investigate the interaction profile of 10-trans, 12-cis conjugated linoleic acid (CLA) with appetite-modulating receptors, specifically the leptin receptor (Leptin-R; PDB ID: 3V6O), and a ghrelin receptor antagonist (6ZYF). Comparative docking analyses were conducted with standard anti-obesity pharmacological agents including Metformin, Rosuvastatin and Vildagliptin to evaluate the relative binding efficacy of CLA. All computational simulations were performed using AutoDock Vina, preceded by rigorous ligand and receptor optimization, binding site prediction, and post-docking visualization utilizing PyMOL and BIOVIA Discovery Studio. Furthermore, computational tools such as pkCSM, SwissADME, and the PASS online platform were utilized to predict pharmacokinetic properties and potential biological activities. The docking outcomes demonstrated that CLA is capable of forming stable complexes with both Leptin-R and Ghrelin receptor targets, although its binding affinities were modest in comparison to Vildagliptin and Rosuvastatin. Collectively, these findings underscore the molecular basis of CLA’s interaction with key appetite-regulating targets and suggest its prospective utility in obesity intervention strategies, meriting further experimental and clinical validation.
Cite this article:
Magendran Rajendiran, Shanmugasundaram Palani. Docking Approach for Evaluating the Anti-Obesity Efficacy of 10- trans 12- cis Conjugated Linoleic Acid via Receptor Analysis. Research Journal of Pharmacy and Technology. 2026;19(7):3059-6. doi: 10.52711/0974-360X.2026.00435
Cite(Electronic):
Magendran Rajendiran, Shanmugasundaram Palani. Docking Approach for Evaluating the Anti-Obesity Efficacy of 10- trans 12- cis Conjugated Linoleic Acid via Receptor Analysis. Research Journal of Pharmacy and Technology. 2026;19(7):3059-6. doi: 10.52711/0974-360X.2026.00435 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2026-19-7-22
10. REFERENCES:
1. Camacho S, Ruppel A. Is the calorie concept a real solution to the obesity epidemic? Glob Health Action. 2017 Jan 9; 10(1).
2. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. New England Journal of Medicine. 2017 Jul 6; 377(1): 13–27.
3. Burden of obesity in the Eastern Mediterranean Region: findings from the Global Burden of Disease 2015 study. Int J Public Health. 2018 May 3; 63(S1): 165–76.
4. Ranjit Ambad, Roshan Kumar Jha, Dhruba Hari Chandi, Saurabh Hadke. Association of Leptin in Diabetes Mellitus and Obesity. Research J. Pharm. and Tech. 2020; 13(12): 6295-6299.
5. Geary N. Control-theory models of body-weight regulation and body-weight-regulatory appetite. Appetite. 2020 Jan; 144: 104440.
6. Doo M, Kim Y. Obesity: Interactions of Genome and Nutrients Intake. Prev Nutr Food Sci. 2015 Mar 31; 20(1): 1–7.
7. De Silva A, Salem V, Long CJ, Makwana A, Newbould RD, Rabiner EA, et al. The Gut Hormones PYY3-36 and GLP-17-36 amide Reduce Food Intake and Modulate Brain Activity in Appetite Centers in Humans. Cell Metab. 2011 Nov; 14(5): 700–6.
8. Shahla O. Al-Ogaidi, Sura A. Abdulsattar, Hameed M. J. Al-Dulaimi. The Impact of Serum Leptin, Leptin Receptor and Insulin on Maternal Obesity. Research J. Pharm. and Tech. 2019; 12(7): 3569-3574.
9. Laxminarayana Kurady Bairy, Shakta Mani Satyam, Prakashchandra Shetty. An Insight on pain modulation with Gender and Obesity: A Systematic Review. Research J. Pharm. and Tech. 2020; 13(12): 6284-6290.
10. Ifana Anugraheni, Sri Andarini, Dian Handayani, Titin Andri Wihastuti. Black yeast beta glucan for insulin Resistance Prevention through IL-33, ST2 and Leptin Level: An In vivo Study of an Obesity model using Sprague dawley Rats. Research J. Pharm. and Tech. 2020; 13(12): 6077-6080.
11. Ahrén B. Dipeptidyl Peptidase-4 Inhibitors. Diabetes Care. 2007 Jun 1; 30(6): 1344–50.
12. Mathieu C. Vildagliptin: a new oral treatment for type 2 diabetes mellitus. Vasc Health Risk Manag. 2008 Dec; Volume 4: 1349–60.
13. Ansari JA, Bhandari U, Haque SE, Pillai KK. Enhancement of antioxidant defense mechanism by pitavastatin and rosuvastatin on obesity-induced oxidative stress in Wistar rats. Toxicol Mech Methods. 2012 Jan 23; 22(1): 67–73.
14. B. Lalitha Devi, N.S. Muthiah, K. Satya Narayana Murty, Sanjay Kumar. Effects of 12 weeks Treatment with Conjugated Linoleic acid Supplementation on Body Fat Mass and Lipid Metabolism in Healthy, Obese Individuals - A Pilot Study. Research J. Pharm. and Tech. 2018; 11(3): 996-1000.
15. Pressley H, Cornelio CK, Adams EN. Setmelanotide: A Novel Targeted Treatment for Monogenic Obesity. Journal of Pharmacy Technology. 2022 Dec 30; 38(6): 368–73.
16. Jeyabaskar Suganya, Viswanathan T, Mahendran Radha, Nishandhini Marimuthu. In silico Molecular Docking studies to investigate interactions of natural Camptothecin molecule with diabetic enzymes. Research J. Pharm. and Tech. 2017; 10(9): 2917-2922.
17. Pariza MW, Park Y, Cook ME. The biologically active isomers of conjugated linoleic acid. Prog Lipid Res. 2001 Jul; 40(4): 283–98.
18. Durgam VR, Fernandes G. The growth inhibitory effect of conjugated linoleic acid on MCF-7 cells is related to estrogen response system. Cancer Lett. 1997 Jun; 116(2): 121–30.
19. Park Y, Storkson JM, Albright KJ, Liu W, Pariza MW. Evidence that the trans ‐10, cis ‐12 isomer of conjugated linoleic acid induces body composition changes in mice. Lipids. 1999 Mar; 34(3): 235–41.
20. Doaa Mahdi Omran, Saad Merza Alaraji, Ali Hussein Albayati, Wathiq Essam. Relationship between Ghrelin and Leptin with Insulin Resistance in Obese Patients and Non-Obese Individuals. Research J. Pharm. and Tech. 2018; 11(1): 281-283.
21. Lalit Kumar, Ruchi Verma. Molecular docking based approach for the design of Novel Flavone Analogues as inhibitor of Beta-Hydroxyacyl-ACP Dehydratase HadAB complex. Research J. Pharm. and Tech. 2017; 10(8): 2439-2445.
22. 22 Sonal P. Kumbhar, Pratiksha A. Satpute, Akash Thombare, Shalini Shinde, N. B. Chougule. Molecular Docking and Admet Studies of Nigella sativa Plant against Osteoporosis. Asian Journal of Pharmaceutical Research. 2025; 15(2): 121-6.
23. Padmini R, Sitrarasi R, Razia M. Molecular Docking Studies of Bioactive Compounds from Allium sativum Against EML4-ALK Receptor. Research J. Pharm. and Tech. 2017; 10(11): 3741-3747.
24. Ayyakannu Arumugam Napoleon, Vijay Sharma. Molecular Docking and In-vitro anti-inflammatory evaluation of Novel Isochromen-1-one analogues from Etodolac. Research J. Pharm. and Tech. 2017; 10(8): 2446-2450.
25. Padmini R, Sitrarasi R, Razia M. Molecular Docking Studies of Bioactive Compounds from Allium sativum Against EML4-ALK Receptor. Research J. Pharm. and Tech. 2017; 10(11): 3741-3747.